Pfizer tests how experimental drug moves through the body
NCT ID NCT06267963
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how healthy men absorb, process, and eliminate the experimental drug PF-07220060. Twelve participants received the drug by mouth or by injection. Researchers measured the drug and its breakdown products in blood, urine, and stool to understand how the body handles it. The results will help guide future studies of this drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PF-07220060
- What this could lead to
- If successful, this study will help researchers understand how PF-07220060 moves through the body, which could guide future dosing and development of this drug.
- What could go wrong
- This is a very early Phase 1 study in only 12 healthy men, not patients. It is designed to gather basic information, not to test if the drug works for any disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PRA Health Sciences
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates